What is Vessl Therapeutics?
Vessl Therapeutics is an Israeli company specializing in the development of cell-based therapies. Established in 2000 and headquartered in Yokne'am Illit, Israel, the company operates within the dynamic biotechnology landscape, focusing on innovative therapeutic approaches. Its strategic positioning in Israel, a known hub for technological advancement, further bolsters its potential for groundbreaking research and development in the life sciences.
How much funding has Vessl Therapeutics raised?
Vessl Therapeutics has raised a total of $16M across 1 funding round:
Unspecified
$16M
Unspecified (2021): $16M with participation from RunYoung Capital
Key Investors in Vessl Therapeutics
RunYoung Capital
RunYoung Capital is an investment firm that has participated in Vessl Therapeutics' funding round. Further details on their specific investment focus are not publicly available.
What's next for Vessl Therapeutics?
The recent major strategic investment signals a pivotal growth phase for Vessl Therapeutics. This capital is expected to accelerate the company's research and development initiatives, potentially enabling the advancement of its cell-based therapy pipeline through clinical trials and toward commercialization. The enterprise-level backing suggests confidence from investors in Vessl's long-term vision and its capacity to address unmet medical needs.
See full Vessl Therapeutics company page
